scholarly journals LncRNA CD27-AS1 promotes acute myeloid leukemia progression through the miR-224-5p/PBX3 signaling circuit

2021 ◽  
Vol 12 (6) ◽  
Author(s):  
Yanling Tao ◽  
Jingjing Zhang ◽  
Lulu Chen ◽  
Xin Liu ◽  
Mingkang Yao ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
The Elderly ◽  
Mapk Signaling ◽  
Cure Rate ◽  
Non Coding Rna ◽  
Induced Apoptosis ◽  
Long Non Coding Rna ◽  
Proliferative Ability ◽  
Acute Myeloid

AbstractAcute myeloid leukemia (AML) is a hematological malignancy with a low cure rate, especially in the elderly. Previous studies have shown that long non-coding RNA (lncRNA) may be an important factor in the pathogenesis of hematological malignancies, including acute myeloid leukemia (AML). However, the biological roles and clinical significances of most lncRNAs in AML are not fully understood. LncRNA CD27 Antisense RNA 1 (CD27-AS1), as a member of lncRNA family, has rare reports on its function. In present study, we found that the expression of CD27-AS1 examined by quantitative real-time PCR was markedly increased in the AML patients (N = 40) compared with healthy volunteers (N = 40). The overall survival time was significantly shorter in patients with higher CD27-AS1 expression than that in patients with lower CD27-AS1 (P < 0.01). Furthermore, downregulation of CD27-AS1 in AML cells suppressed proliferative ability, arrested cell cycle in G0/G1 phase, and induced apoptosis. However, CD27-AS1 overexpression further enhanced the malignant phenotype of AML cells. Additionally, CD27-AS1 was proved to increase PBX3 expression through sponging miR-224-5p. CD27-AS1 knockdown blocked the MAPK signaling through PBX3 silencing and further inhibited the cell growth of AML cells. Taken together, we demonstrate that CD27-AS1 may be a potential prognostic biomarker of AML, and our finding also provides a new insight for non-coding RNA-based therapeutic intervention of AML.

scholarly journals Iluntasunetik argirantz, genoma ez-kodetzailea kodetuz

2019 ◽  
Vol 3 (1) ◽  
Author(s):  
Xabier Agirre ◽  
Naroa Gimenez ◽  
Ane Amundarain
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Non Coding Rna ◽  
Long Non Coding Rna ◽  
Acute Myeloid

 Azken urteetan gertatu den genomen ikerketarako teknologien garapen ikaragarriak zientzialariek genoma, transkriptoma eta proteomaren inguruan zuten ikuspegia errotik aldatzea eragin du. DNAren eta RNAren sekuentziazio masiboei esker, ordura arte “DNA zabor” bezala ezagututako guneetatik transkribatutako proteinarik kodetzen ez duten milaka RNA ez-kodetzaile (ncRNA) detektatu dira, genomen inguruko ikuspegi proteozentrikoa alboratuz eta RNA ez-kodetzaileak, bereziki luzeak (long non-coding RNA, lncRNA), ikertzaileen fokuan jarriz. Era berean, azken ikerketek geneen adierazpenerako ezinbestekoak diren transkripzio- eta itzulpen-prozesuen erregulazioak duen garrantzia ere agerian jarri dute. Erregulazio-mekanismo nagusietako bat DNAn, RNAn eta proteinetan aurkitu diren marka biokimiko itzulgarriek osatzen dute; eta horien ikerketak epigenomika, epitranskriptomika eta epiproteomika izeneko biologiaren atal berrien sorrera ekarri du. Hala ere, ikerketa gehienak epigenoma eta epiproteomaren inguruan egin direnez, marka horien ezarpenak RNAn duen eraginak ezezaguna izaten jarraitzen du. Emaitza hauek tarteko, zalantzarik gabe RNAren biologiaren esparruan galdera asko dago oraindik erantzuteko. Hori dela-eta, berrikuspen honetan aipatutako RNAren biologiaren bi esparru berrietan fokuratu gara, horien inguruan ezaguna dena jasoz eta giza gaixotasunekin, zehazki leuzemia mieloide akutuarekin (Acute myeloid leukemia-AML), duten harremana laburbilduz. Oraindik alor ezezagunak izanik, ikertzaileek tamaina eta konplexutasun handiko erronka dute aurrean RNAren biologiaren mundu ilun hau argitu ahal izateko eta emaitza hauek arlo klinikora bideratzeko. 

Sign in / Sign up

Export Citation Format

Share Document